Welcome to our dedicated page for Elutia news (Ticker: AZYO), a resource for investors and traders seeking the latest updates and insights on Elutia stock.
Elutia Inc. (AZYO) specializes in biologic solutions that enhance medical device compatibility, focusing on orthopedic applications and tissue remodeling technologies. This page provides essential updates on corporate developments, regulatory actions, and clinical advancements.
Key resources include official statements on product safety initiatives like the voluntary bone matrix suspension, progress reports on innovations such as the CanGaroo implant, and financial disclosures. All content is vetted from primary sources including FDA communications and company filings.
Visitors will find updates on quality control measures, partnership announcements with healthcare authorities, and executive commentary from CEO Dr. Randy Mills. Bookmark this page for real-time access to earnings reports, strategic initiatives, and material event disclosures.
For direct access to Elutia's investor materials or to review official regulatory submissions, visit the dedicated investor portal. Check back regularly for verified updates on product pipelines and corporate governance matters.
Aziyo Biologics (Nasdaq: AZYO) will participate in the upcoming Piper Virtual Healthcare Conference from December 1-3, 2020. The company specializes in regenerative medicine, focusing on enhancing surgical outcomes for patients with implantable medical devices. A fireside chat will be available the week of November 23, 2020, accessible through the Investors section of their website. Founded in 2015, Aziyo has developed a portfolio of products for cardiovascular, orthopedic, and reconstructive specialties.
Aziyo Biologics, Inc. and Surgalign Holdings, Inc. have expanded their distribution agreement, allowing Surgalign to distribute the new ViBone® Moldable product in the U.S. This innovative bone graft solution aims to improve spinal fusion surgeries, joining other advanced orthobiologic solutions currently offered by Surgalign. The orthopedic and spinal repair market presents a significant opportunity, valued at approximately $2 billion annually, with 1.5 million procedures using biologic materials. The partnership is positioned to enhance patient outcomes and surgeon experiences.
Aziyo Biologics has secured a group purchasing agreement with Premier Inc. for its CanGaroo Envelope, effective December 1, 2020. This FDA-cleared extracellular matrix (ECM) product is intended for cardiac implantable electronic devices (CIED) and aims to mitigate complications associated with such devices. CEO Ron Lloyd expressed enthusiasm about this recognition and the opportunity to enhance patient outcomes by making CanGaroo available to Premier's extensive network of healthcare providers.
Aziyo Biologics, a regenerative medicine company, plans to release its third quarter earnings results on November 19, 2020, after market close. A conference call will follow at 4:30 p.m. Eastern Time. Investors can access the call via phone or through a live webcast on the company's website. Aziyo focuses on developing differentiated medical products that improve surgical outcomes, particularly for patients with implantable devices. Since its inception in 2015, the company has built a portfolio for cardiovascular, orthopedic, and reconstructive applications.
Aziyo Biologics, Inc. (Nasdaq: AZYO) has priced its initial public offering at $17.00 per share, offering a total of 2,941,176 shares of common stock. This includes 2,205,882 shares of Class A and 735,294 shares of Class B common stock. The IPO aims to raise gross proceeds of $50 million, expected to close on October 13, 2020. Underwriters have a 30-day option to purchase an additional 441,176 shares. Trading under the ticker symbol AZYO will commence on October 8, 2020, with Piper Sandler and Cowen acting as joint book-running managers.
Aziyo Biologics has announced that Maybelle Jordan and Brigid Makes have joined its board of directors, enhancing expertise in biologics and medical devices. Jordan brings over 17 years of experience with Biomerix, while Makes has a strong background in finance and management from various medical firms. CEO Ron Lloyd expressed confidence that their contributions will strengthen the company’s product portfolio and customer relationships. Aziyo focuses on regenerative medicine, particularly for patients using implantable medical devices, and aims to improve surgical outcomes.
FAQ
What is the market cap of Elutia (AZYO)?
